MNTA Momenta Pharmaceuticals Inc.

11.39
+0.21  (+2%)
Previous Close 11.18
Open 11.14
Price To Book 3.6
Market Cap 895346840
Shares 78,608,151
Volume 467,500
Short Ratio
Av. Daily Volume 954,358

SEC filingsSee all SEC filings

  1. 424B5 - Prospectus [Rule 424(b)(5)] 181224070
  2. 8-K - Current report 181224040
  3. 424B5 - Prospectus [Rule 424(b)(5)] 181218738
  4. 8-K - Current report 181218652
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 181167287

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial met primary endpoint - November 29, 2016.
M923
Moderate-to-severe chronic plaque psoriasis
Filed 2007. Approved April 16 2015.
Generic Copaxone
Multiple sclerosis
Phase 2 development discontinued due to poor efficacy shown
Necuparanib (MOM-M402-103)
Advanced metastatic pancreatic cancer
Phase 1 trial to be completed 2019.
M230 (CSL730)
Healthy volunteers
Phase 2 trial to be initiated 4Q 2018.
M281
generalized myasthenia gravis (gMG)
Phase 2 trial to be initiated 4Q 2018.
M281
hemolytic disease of the fetus and newborn (HDFN)

Latest News

  1. Edited Transcript of MNTA earnings conference call or presentation 7-Nov-18 1:00pm GMT
  2. Here's Why Momenta Pharmaceuticals Fell for a Second Straight Day
  3. Momenta Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriter’s Option to Purchase Additional Shares
  4. Teva (TEVA) Stock Poised to Record Big Gains in 2019?
  5. Here's Why Momenta Pharmaceuticals Jumped 18% on Friday
  6. The Daily Biotech Pulse: FDA Nod For Roche, Bristol-Myers Hikes Dividend, 2 Biotechs To Debut
  7. Momenta Pharmaceuticals Announces Pricing of Public Offering of Common Stock
  8. See what the IHS Markit Score report has to say about Momenta Pharmaceuticals Inc.
  9. The Daily Biotech Pulse: AbbVie Halts Lung Cancer Trial, Oncomed Merges With Mereo, Momenta Offering
  10. Momenta Pharmaceuticals Announces Proposed Public Offering of Common Stock
  11. Momenta Pharmaceuticals Provides Update on US Regulatory Strategy for M923, Proposed Biosimilar to HUMIRA®
  12. Factors of Influence in 2018, Key Indicators and Opportunity within Eclipse Resources, DISH Network, Navigant Consulting, TreeHouse Foods, Momenta Pharmaceuticals, and Party City Holdco — New Research Emphasizes Economic Growth
  13. Why Abbvie Is Down 5% in 2018 So Far
  14. Momenta Moves On
  15. Momenta (MNTA) Reports Narrower-Than-Expected Loss in Q3

SEC Filings

  1. 424B5 - Prospectus [Rule 424(b)(5)] 181224070
  2. 8-K - Current report 181224040
  3. 424B5 - Prospectus [Rule 424(b)(5)] 181218738
  4. 8-K - Current report 181218652
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 181167287
  6. 8-K - Current report 181164665
  7. 8-K/A [Amend] - Current report 181134762
  8. 8-K - Current report 181117290
  9. 8-K - Current report 181095763
  10. S-8 - Securities to be offered to employees in employee benefit plans 181007224